The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

Sarepta Therapeutics (NASDAQ:SRPT) said late Monday it will pause all shipments of its Duchenne muscular dystrophy gene ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

ProPublica reporter David Epstein was contacted by a woman with a wild story and a batch of photos she believed were clues to ...

A father of two sons diagnosed with muscular dystrophy is organizing a cornhole tournament this weekend to raise money for ...

Norwegian documentary, The Remarkable Life of Ibelin, directed by Benjamin Ree, chronicles the life of Mats Steen, who had ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

AI-based digital twin modeling predicts patient-specific decline, addressing key trial design and biomarker challenges in FSHD ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...